News
-
-
PRESS RELEASE
VeonGen Announces Clinical Progress of VG801 Gene Therapy in Stargardt Disease, with an Oral Presentation at ARVO 2026
VeonGen announces positive clinical progress of VG801 gene therapy for Stargardt Disease, including FDA and RMAT support, with promising efficacy and safety profile. Presentation at ARVO 2026 -
-
-
-
PRESS RELEASE
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
VeonGen Therapeutics (formerly ViGeneron) announces FDA Rare Pediatric Disease Designation and clinical progress for lead gene therapy VG801 in Stargardt Disease, advancing genetic medicine in ophthalmology and beyond
